Efficacy of Cheiranthus Cheiri in the Treatment of Pericoronitis: A Double-blind, Randomized, Placebo-controlled Trial with Molecular Docking

• DOI: 10.4103/dmr.dmr_9_24
• Publication Date: 2025-05-24T19:00:15Z
• Authors: Shubhamoy Ghosh; Aritra Roy Chowdhury; Sarbendu Paul; Avipsha Sarkar; Abhijit Rana; Mousumi Koley; Indrani Halder; Suman Chandra; Subhranil Saha
• Keywords: Docking (animal)

Context: Pericoronitis is the soft-tissue inflammation surrounding dental crown in a semi-erupted lower third molar. Patients with early-stage pericoronitis experience discomfort, redness, swelling, mucosal ulceration, and loss of function. There dearth evidence-based, standardized treatments for pericoronitis. Aim: This trial attempted to explore efficacy Cheiranthus cheiri (CC) 30 cH against placebos treatment by detecting group differences pain on visual analog scale (VAS) over 14 days intervention. Subsequently, molecular docking CC was performed predict binding affinity ligands receptor proteins. Materials Methods: A 14-day, double-blind, randomized (2:1), placebo-controlled undertaken at Dental Outpatient Department D. N. De Homoeopathic Medical College Hospital. Sixty participants were receive either 12 doses ( n = 40) or identical-looking 20). All instructed gurgle warm saline water 2–3 times day. The primary outcome measure time (days) resolution pain, measured using 100 mm VASs, from baseline up days. Secondary measures included swelling trismus, days; blood erythrocyte sedimentation rate, C-reactive protein, total leukocyte count; Oral Health Impact Profile-14 questionnaire, after intention-to-treat sample analyzed; Kaplan–Meier analysis Welch t -tests unequal variances run detect differences. results examined Biovia’s Discovery Studio Visualizer. Results: Days significantly less than placebo (Mantel-Cox log-rank test: P =0.042). Similar significant also obtained 0.007) trismus 0.014) favoring 30cH placebos; however, no demonstrated other secondary outcomes. During docking, all bioactive components reacted tumor necrosis factor-α, proving verifying its anti-inflammatory potential. Conclusion: produced benefits resolving earlier placebos. Larger trials are warranted substantiate findings. Trial registration: CTRI/2023/04/051254; UTN: U1111-1289-9815.